Current Report Filing (8-k)
September 13 2018 - 5:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 13, 2018
ALTIMMUNE, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-32587
|
|
20-2726770
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
910 Clopper Road, Suite 201S
Gaithersburg, Maryland
|
|
|
|
20878
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
Registrants telephone number including area code: (240)
654-1450
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule
12b-2
of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.03
|
Amendments to Article of Incorporation or Bylaws; Change in Fiscal Year.
|
On September 13, 2018, Altimmune, Inc. (the Company) filed a Certificate of Amendment to its Amended and Restated Certificate
of Incorporation (the Certificate of Incorporation) with the Secretary of State of Delaware to effect a
one-for-thirty
(1:30) reverse split of the
Companys outstanding common stock, par value $0.0001 per share (the Reverse Stock Split). The Reverse Stock Split will reduce the number of the Companys outstanding shares of common stock from approximately 43 million
shares to approximately 1.4 million shares. The number of authorized shares of common stock will remain unadjusted as a result of the Reverse Stock Split. The Reverse Stock Split became effective after the close of market on September 13,
2018 and the consolidated common stock will begin trading on The Nasdaq Global Market on a split-adjusted basis on September 14, 2018.
Additionally, on September 13, 2018, the Company filed a Certificate of Amendment to the Certificate of Incorporation to increase the
number of authorized shares of common stock from 100,000,000 to 200,000,000.
Copies of the Certificates of Amendment are attached as
Exhibit 3.1 and Exhibit 3.2 to this Current Report on Form
8-K
and are incorporated by reference herein.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
ALTIMMUNE, INC.
|
|
|
By:
|
|
/s/ William Enright
|
|
|
Name: William Enright
|
|
|
Title: President and Chief Executive Officer
|
Dated September 13, 2018
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Apr 2023 to Apr 2024